+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome)



Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome)



European Review for Medical and Pharmacological Sciences 15(3): 253-258



Hunter syndrome or mucopolysaccharidosis II (MPS II) is a rare X-linked disease caused by a deficiency of the iduronate-2-sulphatase (12S) lysosomal enzyme, resulting in a progressive accumulation of glycosaminoglycans (GAGs). Enzyme replacement therapy (ERT) with recombinant human 12S idursulfase has been used infrequently in children < 5 years. We present the case of a 7 years and 10 months-old child, who was diagnosed with a severe form of MPS II at the age of 3 years, and who began a 36 months' treatment with idursulfase at 4 years 10 months. After 10 months, GAG urinary excretion was normal, but after just 4 months the liver and spleen had decreased in size, returning to normal limits by 36 months. Significant bone remodeling was noted after 16 months. Cardiac and neurological development, however, progressively deteriorated. The only adverse reactions were episodic inflammations of the upper and/or lower respiratory tract, but there was no otitis. Early use of ERT, presuming good treatment adherence, can significantly improve bone abnormalities.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054164597

Download citation: RISBibTeXText

PMID: 21528770


Related references

Idursulfase: enzyme replacement therapy for mucopolysaccharidosis Type II (Hunter syndrome). Expert Review of Endocrinology and Metabolism 2(1): 19-26, 2019

Idursulfase: enzyme replacement therapy for mucopolysaccharidosis Type II (Hunter syndrome). Expert Review of Endocrinology & Metabolism 2(1): 19-26, 2007

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database of Systematic Reviews 2014(1): Cd008185, 2014

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database of Systematic Reviews 2012(11): Cd008185, 2012

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database of Systematic Reviews 2: Cd008185, 2016

Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatrica . Suppl. 91(439): 98-99, 2003

Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatrica 91(11): 98-99, 2002

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics 167(3): 267-277, 2007

Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome). Journal of Korean Medical Science 29(2): 254-260, 2014

Hunter syndrome (Mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation. Minerva Pediatrica 65(5): 487-496, 2014

Clinical benefit of enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome). 2007

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Molecular Genetics and Metabolism 90(3): 329-337, 2006

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genetics in Medicine 8(8): 465-473, 2006

A phase Ii/Iii clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis Ii (Hunter syndrome). Genetics in Medicine 8(8): 465-473, 2006

Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. American Journal of Ophthalmology Case Reports 9: 1-6, 2018